Aging is not only wear and tear — it is amnesia. The genome survives intact, but the chemical annotations that tell each cell which genes to run fade, smear and drift. Epigenetic restoration is the field asking the most audacious question in biology: if the pattern was written once, can it be written back? The "-100" is the aspiration — a century of healthy lifespan.
Every cell in your body carries the same genome. A neuron and a skin cell differ not in the book they own, but in which pages are bookmarked. The bookmarks are epigenetic marks — chiefly methyl groups stamped onto cytosines at CpG sites — and they are laid down, read and erased by dedicated molecular machinery. Aging, in the epigenetic view, is the slow corruption of that annotation layer.
In 2013, Steve Horvath at UCLA showed that methylation levels at just 353 CpG sites predict the biological age of virtually any human tissue — the "Horvath clock". For the first time, aging had a ruler. Every claim of rejuvenation since has had to answer to it.
David Sinclair's lab at Harvard Medical School argues (Cell, 2023) that disrupting the epigenome — without touching the DNA sequence — is itself sufficient to drive aging in mice. Break the filing system, and a young animal turns old. Restore it, and the old tissue remembers.
In 2006 Shinya Yamanaka at Kyoto University converted adult cells back to stem cells with four factors — Oct4, Sox2, Klf4, c-Myc. Full reprogramming erases identity. The discovery that changed longevity science: partial reprogramming — a short pulse, then stop — resets age while the cell remains itself.
Ocampo and colleagues in Juan Carlos Belmonte's lab at the Salk Institute (Cell, 2016) pulsed OSKM cyclically in mice and ameliorated age-associated hallmarks. Lu and colleagues in the Sinclair lab (Nature, 2020) restored vision in old and glaucomatous mice with OSK — no c-Myc. The mouse data is real. The human data does not exist yet.
This field now attracts billions of dollars, and with the money comes noise. Where the science ends and the marketing begins:
Everything above is cells and mice. What about humans? This page now carries the registry check itself — dated, scoped, and re-run quarterly.
A search of ClinicalTrials.gov (API v2, 2026-09-08) for partial epigenetic reprogramming — by intervention, mechanism and sponsor terms — returns exactly one registered interventional human trial: NCT07290244, Life Biosciences' ER-100. An engineered AAV delivers the OSK trio (OCT4, SOX2, KLF4 — three of the four Yamanaka factors) into one eye of participants with open-angle glaucoma or NAION, with doxycycline switching the factors on for 56 days. It is a Phase 1, single-dose, open-label tolerability study: 18 participants estimated, recruiting since 2026-03-02, primary completion estimated May 2027. Registry record.
The same check finds no completed reprogramming trial, no posted efficacy or methylation-clock result, no Phase 2 or 3, and no systemic (whole-body) administration in humans. The first human experiment has begun; the first human result has not. Scope: this check covers ClinicalTrials.gov only — other national and WHO registries, company pipeline pages and preprints were not searched.
The field's giant experiments use transcription-factor genes delivered by viruses — powerful, but hard to dose and hard to target. Panacea Bio Chem's research programme, led by Bogdan Dicoias, explores a complementary route: peptide- and enzyme-mediated epigenetic modulation — designer amino acid chain (AAC) molecules aimed at the writers, erasers and readers of the epigenome, where dosing can be titrated, stopped, and targeted tissue by tissue.
We state the boundary plainly: this is a research direction, not a product and not a therapy. Panacea claims no rejuvenation results. What we publish here is the scientific landscape and our position in it; programme details remain Panacea intellectual property until peer-reviewed disclosure.
Research programme · no clinical claims · no fabricated data
"A gene therapy that rewinds the clock is a thunderstorm — magnificent, and impossible to aim at a single cell. A peptide is a key cut for one lock. Epigenetic restoration will not be won by the loudest intervention but by the most precise one, and precision is what designer amino acid chains are for."
Bogdan Dicoias — Biochemist · AAC Designer · Panacea Bio Chem Ltd
Cells keep identity through methylation marks on the genome; with age the pattern drifts. That drift — measurable by DNA methylation clocks like Horvath's 2013 multi-tissue clock — is epigenetic aging.
Writing the youthful epigenetic pattern back without erasing cell identity. The leading experimental route is partial reprogramming with Yamanaka factors; chemical routes exist in principle.
In cells and mice, yes — Ocampo 2016, Lu 2020, Gill 2022. In humans, no therapy has completed clinical proof. More on the Questions page.
The aspiration: epigenetic age reversal toward a century of healthy lifespan. A direction, not a promise — the credited timeline is on The Story.
One is registered: NCT07290244, Life Biosciences' ER-100 — a Phase 1 single-dose tolerability study delivering OSK by AAV into one eye, recruiting since March 2026. None has completed, and no results are posted. The dated registry status is above; the Questions page carries the full answer.
Recent developments in the field — refreshed 2026-07-26 by Panacea Bio Chem.
The Panacea Technology Universe
Proprietary Panacea Bio Chem Ltd technologies, invented by Bogdan Dicoias — what each one does, and why it leads its class.
Lyoprester®The only dual-chamber cartridge that is autoreconstitution-enabled, vacuum-sealed and argon-fillback.lyoprester.com ↗
P-EARLs™Panacea-Engineered Aseptic Reconstitution Liquid(s) — each tuned to the peptide it wakes.p-earls.com ↗
Peptourbillon™The layered peptide formulation architecture — single- or multi-layer, never a blend.peptourbillon.com ↗
RF Tunnel™The RF-formed central channel through the cake.rftunnel.com ↗
TgShift™Raises the cake’s glass-transition temperature with RF — instead of chilling below it.tgshift.com ↗
Cryolapse™Cryogenic pressure collapse — and the machine that pushes plungers and crimps.cryolapse.com ↗
LyoLevit™The cake levitates and spins in high orbit — driven by ultrasound and RF.lyolevit.com ↗
Lyochrysalis™The integrated chamber housing the whole drying stack.lyochrysalis.com ↗
S3Pulse™The control brain for every piece of Panacea hardware.s3pulse.com ↗
Liquiprester™The single-liquid cartridge engineered so multiple peptide APIs coexist in one shared vehicle.liquiprester.com ↗
Syntheseract™Continuous-flow peptide synthesis in a special, very fast and economical way.syntheseract.com ↗
CFSPPS™Continuous-flow solid-phase peptide synthesis, written as its own category.cfspps.com ↗
OxyDeplete™Degassing plus no-headspace doctrine — the oxygen-starved seal.oxydeplete.com ↗
ArgonLock™The final inert-atmosphere lock under argon.argonlock.com ↗
RedoxVault™Separation, not merely suppression — redox isolation in lipid micro-reservoirs.redoxvault.com ↗
PleniDose™The shared filling gantry — one machine filling both the dual-chamber Lyoprester and the liquid Liquiprester.plenidose.com ↗
IncreSure™The dose-metrology layer — verified API per pen increment.incresure.com ↗
ElimiVoid™Front-void elimination without touching the metered dose.elimivoid.com ↗
Cryoviscous™The characterised cold, high-viscosity, low-mobility conditioning state.cryoviscous.com ↗
Vana Machine™Vacuum Assisted Needle Accessory — vacuum conditioning and plunger-locking for the cartridge.
EZnject™The disposable auto-injector pen built around the Lyoprester.panaceaeznject.com ↗
Dicoias ΨThe computed-chemistry advisory — every substance reduced to a vector across physical, electronic and formulation space.dcppsi.com ↗
SealoPrester™Aseptic Cartridge Closure System — Seal o’ Precision + Sterility.sealoprester.com ↗
Peptidic LiquidThe peptide formulation in solution — the active plus its buffers, cryoprotectants, lyoprotectants and scaffolders.peptidicliquid.com ↗No publication indexed in PubMed in the last 30 days for "epigenetic restoration" OR "epigenetic age reversal" — the most recent in the field, refreshed weekly.